MNITMTNovel, non-toxic immunosuppressive agent CAS# 177653-76-8 |
- Mc-MMAD
Catalog No.:BCC1735
CAS No.:1401963-15-2
- Nocodazole
Catalog No.:BCC3826
CAS No.:31430-18-9
- Colchicine
Catalog No.:BCN6271
CAS No.:64-86-8
- Mc-MMAE
Catalog No.:BCC5201
CAS No.:863971-24-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 177653-76-8 | SDF | Download SDF |
| PubChem ID | 364622 | Appearance | Powder |
| Formula | C7H8N6O2S | M.Wt | 240.24 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | NSC 631156 | ||
| Solubility | Soluble to 10 mM in water | ||
| Chemical Name | 4-methyl-3-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-1,2,4-triazole | ||
| SMILES | CN1C=NC(=C1SC2=NN=CN2C)[N+](=O)[O-] | ||
| Standard InChIKey | NMBDIMPYACLUDE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C7H8N6O2S/c1-11-3-8-5(13(14)15)6(11)16-7-10-9-4-12(7)2/h3-4H,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Novel, non-toxic immunosuppressive agent. Inhibits human mixed lymphocyte reaction in vitro (ED50 = 2.7 μM) and prolongs skin graft survival in mice. Produces a 98.1% reduction in antibody response following oral administration in rabbits. |
MNITMT Dilution Calculator
MNITMT Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.1625 mL | 20.8125 mL | 41.625 mL | 83.2501 mL | 104.0626 mL |
| 5 mM | 0.8325 mL | 4.1625 mL | 8.325 mL | 16.65 mL | 20.8125 mL |
| 10 mM | 0.4163 mL | 2.0813 mL | 4.1625 mL | 8.325 mL | 10.4063 mL |
| 50 mM | 0.0833 mL | 0.4163 mL | 0.8325 mL | 1.665 mL | 2.0813 mL |
| 100 mM | 0.0416 mL | 0.2081 mL | 0.4163 mL | 0.8325 mL | 1.0406 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Glycerol 1-(26-hydroxyhexacosanoate)
Catalog No.:BCN1131
CAS No.:177602-14-1
- ZK 164015
Catalog No.:BCC7272
CAS No.:177583-70-9
- Flavokawain B
Catalog No.:BCN3568
CAS No.:1775-97-9
- 2-Amino-5-nitrobenzophenone
Catalog No.:BCC8537
CAS No.:1775-95-7
- Aglain C
Catalog No.:BCN6604
CAS No.:177468-85-8
- DBeQ
Catalog No.:BCC3916
CAS No.:177355-84-9
- Aglain B
Catalog No.:BCN6636
CAS No.:177262-32-7
- 26-O-Acetylsootepin A
Catalog No.:BCN7699
CAS No.:1772588-99-4
- R 568 hydrochloride
Catalog No.:BCC7781
CAS No.:177172-49-5
- Ambrisentan
Catalog No.:BCC4887
CAS No.:177036-94-1
- 2alpha,19alpha-Dihydroxy-3-oxo-urs-12-en-28-oic acid
Catalog No.:BCN7406
CAS No.:176983-21-4
- LY 320135
Catalog No.:BCC7346
CAS No.:176977-56-3
- NKP608
Catalog No.:BCC1802
CAS No.:177707-12-9
- Proxyfan oxalate
Catalog No.:BCC7378
CAS No.:177708-09-7
- Calystegine N1
Catalog No.:BCN1866
CAS No.:177794-03-5
- Calystegine A6
Catalog No.:BCN1886
CAS No.:177794-04-6
- Eletriptan HBr
Catalog No.:BCC5039
CAS No.:177834-92-3
- Boc-His-OH
Catalog No.:BCC3398
CAS No.:17791-52-5
- Clematichinenoside C
Catalog No.:BCN7850
CAS No.:177912-24-2
- Sauchinone
Catalog No.:BCN2299
CAS No.:177931-17-8
- Allopurinol Sodium
Catalog No.:BCC4886
CAS No.:17795-21-0
- Fmoc-D-Phe(4-NO2)-OH
Catalog No.:BCC3278
CAS No.:177966-63-1
- Aescigenin
Catalog No.:BCC8293
CAS No.:17806-68-7
- Nociceptin (1-13)NH2
Catalog No.:BCC5749
CAS No.:178064-02-3
Comparison of the effects of azathioprine and its novel non-mercaptopurine analog on antibody response in rabbits.[Pubmed:12926553]
Pol J Pharmacol. 2003 Mar-Apr;55(2):239-43.
Azathioprine (AZA) was originally developed as a pro-drug of the cytotoxic agent 6-mercaptopurine (6-MP). It was assumed that the methylnitroimidazole (MNI) group attached to 6-MP served only as thiol protecting moiety and was pharmacologically inactive. However, in this study we confirm that the novel compound, 3-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-4-methyl-1,2,4-triazole (MNITMT) lacking the 6-MP moiety and retaining the MNI group is a better immunosuppressive agent than AZA. Thus, administration of MNITMT (2 mg/kg/day) to rabbits for two weeks caused a statistically significant and consistent inhibition of the antibody response. The onset of immunosuppression was on day 14. However, administration of AZA (2 mg/kg/day) to rabbits for two weeks inhibited the antibody response significantly on day 60 post-treatment. The solvent used to dissolve the above-mentioned drugs had no effect on the antibody response. Neither AZA nor MNITMT had any effect on the blood picture of the treated rabbits indicating no bone marrow toxicity.
Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects.[Pubmed:8709098]
J Med Chem. 1996 Jul 5;39(14):2690-5.
Clinical use of the immunosuppressive drug azathioprine is limited by potentially serious toxic effects related to depression of bone marrow function. The immunosuppressive and toxic properties of azathioprine are regarded as being properties of the cytotoxicity of its metabolite, 6-mercaptopurine (6-MP). However, azathioprine has an immunosuppressive effect additional to that attributable to 6-MP alone, and we propose that this is associated with an action of the methylnitroimidazolyl substituent. This suggests a route to the rational design of nontoxic immunosuppressants by replacing the 6-MP component of azathioprine with nontoxic thiols. We have synthesized and tested in vitro 24 such analogues, with two being further tested in vivo. In the human mixed lymphocyte reaction, virtually all compounds showed some degree of activity, 10 compounds being more active than azathioprine. In vivo, two compounds were more effective than azathioprine at prolonging graft survival in mice. In an oral toxicity study in male CD1 mice at doses equivalent to those at which azathioprine caused severe bone marrow depression both analogues had no toxic effects. Our results show that the immunosuppressive effects and bone marrow toxicity of azathioprine are not a consequence of release of 6-MP alone, and with appropriate modification can be separated, an approach which may lead to less toxic immunosuppressive drugs.
